Analyze the efficacy and functions of Trientine

Trientine(Trientine) is a prescription drug that has been used clinically around the world for many years. It is one of the most representative copper-removing agents in the treatment of Wilson Disease. This disease is a rare hereditary copper metabolism disorder. Patients have limited copper excretion in the body, which causes copper to continuously accumulate in the liver, nervous system and other tissues, causing long-term serious consequences such as liver damage and nervous system disorders. The main pharmacological property of trientine is that it reduces the copper load in the body by chelating free copper and promoting urinary excretion of copper. Compared with traditional penicillamine, it is often regarded as a better-tolerated alternative internationally and is particularly suitable for patients who have adverse reactions to penicillamine or require adjustment of their long-term treatment regimen. Therefore, its use has been expanding in recent years.

From a mechanism perspective, trientine is a polyamine chelator that can form a stable complex with copper, and the complex can be quickly excreted through the kidneys, which makes the drug have a sustained and mild effect in reducing copper deposition in the liver and brain. As more studies focus on the importance of long-term treatment safety in patients with Wilson's disease, trientine is gradually included in global guidelines as one of the first-line copper removal treatment options. It does not rely on protein carriers, so it also has certain advantages for some patients with significantly impaired liver function and large fluctuations in albumin levels. Overseas guidelines also point out that trientine can actually be used as one of the core drugs in the lifelong management of Wilson's disease, especially for patients with moderate or severe liver damage, emphasizing its value in long-term maintenance treatment.

In terms of efficacy, trientine can significantly reduce copper accumulation in the body, relieve liver inflammation and neurological symptoms caused by copper deposition, thereby improving patients' daily functional status and quality of life. In terms of liver performance, the copper-removing effect of the drug can help reduce abnormal indicators such as elevated transaminases, allowing the liver to gradually restore its relatively stable metabolic capacity. For those patients who already have mild to moderate liver fibrosis, long-term treatment with trientine can also help prevent the progression to cirrhosis and reduce the risk of further liver failure. Trientine can also bring some improvement to neurological symptoms, such as tremor, movement incoordination or speech impairment. Although the degree of improvement varies depending on individual differences, its effect trend has been supported by a number of overseas data. Its characteristic is that while its effect is relatively mild, it can reduce the probability of neurological symptoms worsening during treatment, which is difficult for some traditional copper removers to achieve.

Relative to its pharmacological effects, another important value of trientine lies in its safety and tolerability. Since the drug does not contain a sulfur-based structure, the proportion of common adverse reactions is relatively small. Some patients may experience mild stomach discomfort, mild rash or fatigue during the initial stage of treatment, but most can be relieved by adjusting the medication time or dietary management. Overseas data show that trientine has good stability for patients with Wilson's disease who have received maintenance treatment for many years. Most of its adverse reactions are controllable and reversible, which is very consistent with the medication characteristics for long-term management of chronic diseases. As a result, trientine is increasingly being incorporated into standardized treatment pathways for the management of Wilson's disease worldwide.

Reference materials:https://www.cufence.com/